Concomitant chronic myeloid leukemia and monoclonal B cell lymphocytosis - a very rare condition by Sara Duarte, Sónia Campelo Pereira, Élio Rodrigues, Amélia Pereira

Get full text

S156: FRONTLINE ASCIMINIB COMBINATION IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS. THE FASCINATION TRIAL. by Thomas Ernst, Philipp Le Coutre, Martina Crysandt, Tim H Brümmendorf, Georg-Nikolaus Franke, Thomas Illmer, Andreas Burchert, Fabian Lang, Susanne Saussele, Lino Lars Teichmann, Markus Radsak, Stefan Krause, Jenny Rinke, Christian Fabisch, Thomas Lang, Markus Pfirrmann, Andreas Hochhaus

Get full text

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience by Kamal Chamoun, Hagop Kantarjian, Rami Atallah, Graciela Nogueras Gonzalez, Ghayas C. Issa, Mary Beth Rios, Guillermo Garcia-Manero, Gautam Borthakur, Farhad Ravandi, Nitin Jain, Naval Daver, Marina Konopleva, Courtney D. DiNardo, Tapan Kadia, Naveen Pemmaraju, Elias Jabbour, Jorge Cortes

Get full text

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia by Hyacinthe Johnson-Ansah, Benjamin Maneglier, Françoise Huguet, Laurence Legros, Martine Escoffre-Barbe, Martine Gardembas, Pascale Cony-Makhoul, Valérie Coiteux, Laurent Sutton, Wajed Abarah, Camille Pouaty, Jean-Michel Pignon, Bachra Choufi, Sorin Visanica, Bénédicte Deau, Laure Morisset, Emilie Cayssials, Mathieu Molimard, Stéphane Bouchet, François-Xavier Mahon, Franck Nicolini, Philippe Aegerter, Jean-Michel Cayuela, Marc Delord, Heriberto Bruzzoni-Giovanelli, Philippe Rousselot

Get full text

Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia by Raquel Alves, Ana Cristina Gonçalves, Joana Jorge, António M. Almeida, Ana Bela Sarmento-Ribeiro

“…Multidrug resistance (MDR) development has emerged as a complication that compromises the success of several chemotherapeutic agents. In chronic myeloid leukemia (CML), imatinib resistance has been associated with changes in <i>BCR-ABL1</i> and intracellular drug concentration, controlled by SLC and ABC transporters. …”
Get full text

Frequencies of BCR::ABL1 Transcripts in Patients with Chronic Myeloid Leukemia: A Meta-Analysis by Pablo Romero-Morelos, Ana Lilia González-Yebra, Daniela Muñoz-López, Elia Lara-Lona, Beatriz González-Yebra

Subjects: “…chronic myeloid leukemia…”
Get full text

Design of personalized cancer treatments by use of optimal control problems: The case of chronic myeloid leukemia by Pedro José Gutiérrez-Diez, Jose Russo

Subjects: Get full text

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge by Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Massimo Breccia

Subjects: “…chronic myeloid leukemia…”
Get full text

Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes by Hijiya N, Mauro MJ

Subjects: Get full text

Subgaleal hematoma as the first presentation of chronic myeloid leukemia: one case report and literature review by Shi Rui, Zhang Jie, Liang Hongzheng, Yang Linhua, Yang Qing, Wang Kaiyue, Ge Xiaoyan

Subjects: “…|chronic myeloid leukemia|subgaleal hematoma|intraorbital hematoma…”
Get full text

Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment by Claudia Bettoni da Cunha-Riehm, Verena Hildebrand, Michaela Nathrath, Markus Metzler, Meinolf Suttorp

Subjects: Get full text

Chronic myeloid leukemia presenting as an atraumatic splenic rupture in the setting of coronavirus disease 2019 infection by Hanan Alharthy, Jaclyn Clark, Rima Koka, Ali Aldahmashi, Maria R. Baer

Subjects: “…chronic myeloid leukemia…”
Get full text

Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses. by Jiye A, Sixuan Qian, Guangji Wang, Bei Yan, Sujiang Zhang, Qing Huang, Lingna Ni, Weibin Zha, Linsheng Liu, Bei Cao, Ming Hong, Hanxin Wu, Hua Lu, Jian Shi, Mengjie Li, Jianyong Li

“…The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for chronic myeloid leukemia (CML). However, some patients gradually develop resistance to imatinib, resulting in therapeutic failure. …”
Get full text

Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia by Yuanyuan Liu, Hong Song, Huanqing Song, Xiaoxia Feng, Chuan Zhou, Zhifang Huo

Subjects: “…Pediatric chronic myeloid leukemia…”
Get full text

Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib by Kazuma Ohyashiki, Tomohiro Umezu, Seiichiro Katagiri, Chiaki Kobayashi, Kenko Azuma, Tetsuzo Tauchi, Seiichi Okabe, Yutaka Fukuoka, Junko H. Ohyashiki

Subjects: Get full text

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance by Raquel Alves, Ana Cristina Gonçalves, Sergio Rutella, António M. Almeida, Javier De Las Rivas, Ioannis P. Trougakos, Ana Bela Sarmento Ribeiro

“…Resistance to targeted therapies is a complex and multifactorial process that culminates in the selection of a cancer clone with the ability to evade treatment. Chronic myeloid leukemia (CML) was the first malignancy recognized to be associated with a genetic alteration, the t(9;22)(q34;q11). …”
Get full text

Issues in current management of chronic myeloid leukemia: Importance of molecular monitoring on long term outcome by Hari Menon

Get full text

Transcriptomics-Based Characterization of the Toxicity of ZnO Nanoparticles Against Chronic Myeloid Leukemia Cells by Alsagaby SA, Vijayakumar R, Premanathan M, Mickymaray S, Alturaiki W, Al-Baradie RS, AlGhamdi S, Aziz MA, Alhumaydhi FA, Alzahrani FA, Alwashmi AS, Al Abdulmonem W, Alharbi NK, Pepper C

“…To the best of our knowledge, the toxicity of ZnO NPs against human chronic myeloid leukemia cells (K562 cell line) has not been studied using transcriptomics approach.Objective: The goals of this study were to evaluate the capability of ZnO NPs to induce apoptosis in human chronic myeloid leukemia cells (K562 cells) and to investigate the putative mechanisms of action.Methods: We used viability assay and flowcytometry coupled with Annexin V-FITC and propidium iodide to investigate the toxicity of ZnO NPs on K562 cells and normal peripheral blood mononuclear cells. …”
Get full text

Priapism as the first manifestation in chronic myeloid leukemia: A case report and focused review of literature by Claudia Lucia Sossa Melo, Carlos Alberto Orozco Orozco, Angela Maria Peña Castellanos, Maria Alejandra Rueda Perea, Cristian Orlando Porras Bueno, Carlos Ivan Romero Diaz, Helga Natalia Rojas Rodríguez

“…The patient was subsequently diagnosed with chronic myeloid leukemia. Priapism is a rare manifestation of chronic myeloid leukemia (≤ 3%) and occurs mostly due to hyperleukocytosis, resulting in thrombus formation and corporal venous outflow obstruction. …”
Get full text

Variables associated with pulmonary hypertension screened by echocardiography in chronic myeloid leukemia patients on dasatinib therapy by Wenying Jin, Sen Yang, Chao Yu, Tiangang Zhu, Qian Jiang, Qian Jiang

“…This study aimed to explore the variables associated with PH by echocardiography in patients with chronic myeloid leukemia in the chronic phase (CML-CP) receiving dasatinib therapy.MethodsEchocardiography was performed to estimate the probability of PH and pulmonary artery systolic pressure (PASP). …”
Get full text